MiNA Therapeutics bags nearly $30M Series A to push activating mRNA tech through the clinic
Seven years after leaving investment banking to take the helm at MiNA Therapeutics, CEO Robert Habib is on a mission to develop a “new class of medicines” using small activating mRNA technology. And on Thursday, the London-based biotech announced it landed a modest £23 million (nearly $30 million) Series A to work with.
Habib’s father, the prominent Imperial College London professor Nagy Habib, co-founded MiNA in 2008. The company’s lead mRNA program is designed to “switch genes on,” and potentially help treat what the CEO called “the undruggable”: difficult-to-treat diseases, starting with liver cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.